Literature DB >> 11535315

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs.

T T Le1, D Drane, J Malliaros, J C Cox, L Rothel, M Pearse, T Woodberry, J Gardner, A Suhrbier.   

Abstract

CD8 alphabeta cytotoxic T lymphocyte (CTL) polyepitope or polytope vaccines have traditionally been delivered using recombinant vector or DNA based delivery modalities. Here we show the delivery of polytope vaccines in the form of either synthetic polypeptides or recombinant polytope proteins by ImmunoStimulatory COMplexes (ISCOMs(R)). Induction of multiple protective CTL responses by these polytope-ISCOM formulations were comparable to viral vector or DNA based delivery modalities as assessed by IFNgamma ELISpot, chromium release and viral challenge assays. Measurement of CTL responses specific for the different epitopes revealed immunodominance patterns, which were largely independent of the vaccine vector or the order of the epitopes in the polytope. ISCOMs thus emerge as a viable human delivery modality for protein-based polytope vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535315     DOI: 10.1016/s0264-410x(01)00243-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Authors:  Tracey J Harvey; Itaru Anraku; Richard Linedale; David Harrich; Jason Mackenzie; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

5.  Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.

Authors:  Wenyi Gu; Melanie Cochrane; Graham R Leggatt; Elizabeth Payne; Allison Choyce; Fang Zhou; Robert Tindle; Nigel A J McMillan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

6.  Overlapping synthetic peptides as vaccines.

Authors:  Shisong Jiang; Ruijiang Song; Sergei Popov; Saied Mirshahidi; Ruth M Ruprecht
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

7.  SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation.

Authors:  C Sylvester-Hvid; M Nielsen; K Lamberth; G Røder; S Justesen; C Lundegaard; P Worning; H Thomadsen; O Lund; S Brunak; S Buus
Journal:  Tissue Antigens       Date:  2004-05

8.  Kunjin replicon-based simian immunodeficiency virus gag vaccines.

Authors:  Itaru Anraku; Vladislav V Mokhonov; Paweena Rattanasena; Ekaterina I Mokhonova; Jason Leung; Gorben Pijlman; Andrea Cara; Wayne A Schroder; Alexander A Khromykh; Andreas Suhrbier
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.